performance liquid chromatography with fluorescence [29, 30] or UV detection [31] [32] [33] [34] [35] , liquid chromatography tandem mass spectrometry (LC/MS/MS) [36, 37] and capillary electrophoresis [38, 39] are also reported for determination of moxifloxacin hydrochloride from human body fluids. British Pharmacopoeia (BP) [40] employs HPLC method for the assay of moxifloxacin hydrochloride in pharmaceutical preparations. Further, the BP describes no environmentally friendly chromatographic procedure since acetonitrile is one of the components of mobile phase.
Introduction
Moxifloxacin (Figure 1 ), 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo [3,4-b] pyridin-6-yl] 4-oxo-3-quinoline carboxylic acid [1] is a new fourth generation 8-methoxy fluoroquinolone antibacterial agent with a broad spectrum and improved activity against gram-positive bacteria (including staphylococci, streptococci, enterococci), anaerobes and atypical bacteria [2] . Various methods have been reported for the analysis of moxifloxacin in pharmaceutical dosage forms by flow injection with chemiluminescence detection [3] , atomic absorption spectrometry [4] , atomic absorption spectroscopy, conductometry and colorimetry [5] , spectrophotometry [4, [6] [7] [8] [9] [10] , kinetics spectrophotometry [4, [11] [12] [13] , voltammetry [14, 15] , differential pulse polarography [16] , spectrofluorimetry [17] [18] [19] and capillary electrophoresis [20, 21] . Chromatographic methods such as reversed-phase HPLC/fluorescence [22] [23] [24] , HPLC with ultra violet detection [25] [26] [27] and high-performance thin-layer chromatography [28] have been reported for the estimation of moxifloxacin hydrochloride in pharmaceutical products. Voltammetry [14, 15] , spectrofluorimetry [17] , high- system equipped with a binary pump, degasser, column oven, auto sampler and photodiode array (PDA) detector containing a quartz flow cell (10 mm path and 13 L volume). The HPLC system was well equipped with Ezchrom Elite Hitachi software for data processing. Other instruments like Metrohm compact titrator, Sartorius analytical balance, WTW pH meter and Dihan sonicator were used in sample and standard preparations.
Chromatographic conditions
The column used was Nucleodur C18 (250×4.6 mm, 5 m particle size, Macherey-Nagel Germany). The mobile phase was 0.1 M formic acid and methanol in the ratio of 30:70, filtered through nylon 0.45 m membrane filter and degassed by ultrasonic agitation before use. The mobile phase was prepared weekly and has a flow rate of 1.0 mL/min. The injection volume was 10 L with ambient column oven temperature. Isocratic elution of all analytes was monitored at 280 nm.
Standard solutions and calibration graph
Stock solution of moxifloxacin hydrochloride containing 2.0 mg/mL was prepared in HPLC grade methanol. Further dilutions from stock solution were made using methanol as a solvent. Stock solution of rosuvastatin calcium containing 1.0 mg/mL was prepared in methanol. Solutions were found to be stable for one month at least when stored in the dark at 2-8 °C. A series of working standard solutions of MOXF equivalent to 1.12-590.0 µg/mL were prepared by diluting the stock standard solution with the methanol. In each sample 6 mL of ROSV was added (600 µg/mL in the final volume). To construct the calibration curve five replicates (10 L) of each standard solution were injected immediately after preparation into the column and the peak area of the chromatograms were measured. Then, the mean peak area ratio of MOXF to that of the internal standard was plotted against the corresponding concentration of MOXF to obtain the calibration graph.
Sample preparation
An accurately weighed quantity of powdered tablets equivalent to 200 mg of MOXF was transferred into 100 mL volumetric flask and extracted with 50 mL methanol in an ultrasonic bath for 10 min. The volume was completed with methanol and filtered. A suitable concentration was prepared by diluting 0.5 mL of the filtrate with methanol to 10 mL in volumetric flask containing 6 mL of the internal standard. The solution was then analyzed as mentioned under the construction of calibration graphs.
Results and Discussion
Method development and optimization of chromatographic conditions Rosuvastatin calcium ( Figure 1 ) was used as internal standard (I.S.), to improve the analytical performance and thus control undetermined changes in active pharmaceutical ingredient concentration and instrument response fluctuations, and also to reduce the problem of the many-fold dilution required in the classical batch procedures.
In this study, Nucledur C18 column gave the most suitable resolution between MOXF and ROSV peaks (>4) according to the pharmacopeial requirement while the other columns (Nucleodur C8, Hichrom 5 C8, ODS Hypersil C18) cause the peaks of the MOXF and ROSV either to be overlapped or to have unsuitable resolution (<4).
To optimize the best conditions for separation of MOXF from internal standard, the effects of methanol volume percentage (60-80%), flow rate (0.8-1.3 mL/min), concentration of formic acid (0.1-0.7 M) and pH of the aqueous solution (2.30-2.90) were studied. Factor levels are given in parenthesis. For all experimental concentration values, the drugs are eluted in order of MOXF and ROSV.
The percentage of methanol in the mobile phase had a significant effect on the retention behavior of the studied compounds. A satisfactory separation of MOXF and ROSV with satisfactory resolution and increased speed was obtained with a mobile phase containing 70% methanol. An increase in the percentage of methanol decreases the retention of compounds; MOXF and ROSV. Increasing methanol percentage to more than 80% MOXF peak is eluted with the solvent front, while at methanol percentage lower than 60% the elution of ROSV peak is seriously delayed, as shown in Figure 2 .
For further optimization, formic acid concentrations at different pH values (ranging from 2.30 to 2.90) were tried as the aqueous phase along with 70% methanol in the mobile phase. Interestingly very good separation was achieved on a C18 stationary phase with the mobile phase in which the pH of the aqueous phase was adjusted to 2.80. Finally the mobile phase consisting of methanol: 0.1 M formic acid adjusted to pH 2.80 in a ratio of (70:30, v/v) at a flow rate of 1.0 mL/min was found appropriate allowing adequate separation of MOXF and ROSV. Injection volume 10 μL and run time 9 min.
The use of isocratic elution was proven to be short retention time for the MOXF peak and helped in the separation of MOXF and ROSV. Figure 3 shows a typical chromatogram obtained by the proposed RP-HPLC method, demonstrating the resolution of the symmetrical peaks corresponding to MOXF and ROSV with a flow rate of 1.0 mL/min. The retention time of MOXF and ROSV was about 2.027 and 7.680 min, respectively. The retention time observed allows a fast determination of the drug, which is suitable for QC laboratories. The optimum wavelength for detection was at 280 nm, at which the best detector responses for all substances were obtained.
Method validation
The method was validated according to ICH guidelines [41] . The following validation characteristics were addressed:
System suitability
System suitability tests are an integral part of a liquid chromatographic method, and they were used to verify that the proposed method was able to produce good resolution between the peaks of interest with high reproducibility. The system suitability was determined by making seven replicate injections from freshly prepared standard solutions (containing 100 µg/ mL of MOXF in the presence of 600 µg/mL of internal standard) and analyzing each solute for their peak area, theoretical plates, resolution, tailing factors, capacity factor and selectivity. The system suitability requirements for MOFX and ROSV were a % RSD of peak areas less than 0.36%, peak tailing factor less than 1.02 and peak resolution greater than 4.0 between adjacent peaks for the analyte. This method met these requirements. The results of system suitability test in comparison with the required limits are shown in Table 1 . According to the results presented, the proposed method fulfils these requirements within the accepted limits.
Specificity
Specificity is the ability of the method to accurately measure the analyte response in the presence of all potential sample components. The specificity of the chromatographic method was determined to ensure separation of MOXF and ROSV as illustrated in Figure 3 where complete separation of MOXF was noticed. The HPLC chromatogram recorded for the analyte in tablet ( Figure  4) showed almost no peaks within a retention time range of 9 min. The figure show that MOXF is clearly separated and the peak of analyte was pure and excipients in the formulation did not interfere the analyte.
Linearity and limits of detection and quantification
The calibration curve for MOXF was constructed by ploting the ratio of the peak area of MOXF to peak area of the internal standard (ROSV) against the concentratation. The plot showed a linear range 1.12-590.0 μg/mL for MOXF with correlation coefficient of the regression equation [42] greater than 0.999 in all cases and results are summarized in Table 2 .
The limit of detection (LOD) and limit of quantification (LOQ) were determined experimentally. LOD was expressed as the concentration of compound that generated a response to three times of the signal to-noise (S/N) ratio, and LOQ was 10 times of the S/N ratio [43] . The LOD and LOQ parameters were determined from regression equations of MOXF; LOD (k=3) =k×S a /b, LOQ (k=10) =k×S a /b (where b is the slope of the calibration curve and S a is the standard deviation of the intercept). LOD and LOQ were 0.23 and 0.78 µg/mL, respectively, showed good sensitivity of the proposed method.
Accuracy and precision
Intra and inter-day precision of the method were determined of MOXF at concentrations of 1.12, 20, 50, 100, 200, 400 and 590 µg/mL and of ROSV at the concentration used in the assay (600 µg/mL) from bulk and formulations, an identical set of standards prepared in the methanol was analysed. Absolute recoveries at each concentration were measured by comparing the response of pre-treated standards with the response of standards which had not been subjected to sample pre-treatment.
Accuracy was determined by calculating the recovery. The method was found to be accurate with % recovery 100.07%-103.85% for MOXF (Table 3) .
Precision: a) Variation of results within the same day (intraday), variation of results between days (inter-day) was analyzed. For intra-day (n=5) % RSD was found to be 0.34-1.77% and % RSD for inter-day (n=5) was 0.38-1.80%. The % RSD is < 2 which indicate that the method is precise (Table 3 ). b) Repeatability data are shown in Table 5 . The % RSD is < 2 for MOXF which indicate that the method is precise.
Robustness
Robustness of HPLC method was determined by deliberately varying certain parameters like flow rate, percentage of organic solvent in mobile phase and pH of mobile phase. For all changes in conditions the samples were analysed in triplicate. When the effect altering one set of conditions was tested, the other conditions were held constant at optimum values.
The robustness was investigated by achieving deliberate changes in concentration of formic acid by ± 0.02 M, flow rate by ± 0.1 mL/min and change in methanol composition of mobile phase by ±5%. Robustness of the method was carried out in triplicate at a concentration of 100 µg/mL. The system suitability parameters remained unaffected over deliberate small changes in the chromatographic system, illustrating that the method was robust over an acceptable working range of its HPLC operational parameters (Table 4) .
Method application
The proposed, developed and validated method was applied to determine MOXF in its marketed formulations as shown in Figure 4 and Table 5 . As can be seen from Table 5 , the proposed methods have the advantages of being virtually free from interferences by excipients commonly found in tablets or from by performing replicate (n=5) analyses of standards and samples. Intra-day assay variation was evaluated by injecting these samples in the same day. Inter-day assay variation was evaluated by injecting these samples on 7 different days from day 1 to 30 after preparation. Recovery study was performed in view to justify accuracy of the proposed method. To determine recovery
